Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

789
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
789

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing Automated Lyumjev® Delivery with Carbohydrate Counting, Qualitative Meal-Size Estimation, and Fully Closed-Loop in Type 1 Diabetes: A Pilot, Randomized, Crossover Trial.

Diabetes technology & therapeutics·2026
Same author

Design and Evaluation of a Novel Clinical Decision Support Algorithm for Weekly Insulin Efsitora Alfa.

Journal of diabetes science and technology·2026
Same author

A hierarchical network model for the estimate of the energy expenditure in individuals with type 1 diabetes.

Engineering applications of artificial intelligence·2026
Same author

Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report.

Journal of diabetes science and technology·2026
Same author

Autoregressive With Exogenous Input (ARX) Decision Support for Blood Pressure Maintenance During Cesarean Delivery Under Spinal Anesthesia: A Prospective Pilot Study With Matched Nonconcurrent Controls.

medRxiv : the preprint server for health sciences·2026
Same author

Research Code Sharing in Support of Gold Standard Science.

Journal of diabetes science and technology·2026

Related Experiment Video

Updated: Mar 10, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Enhanced Model Predictive Control (eMPC) Strategy for Automated Glucose Control.

Joon Bok Lee1, Eyal Dassau1, Ravi Gondhalekar2

  • 1Department of Chemical Engineering, University of California, Santa Barbara, CA 93106, USA; Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, 29 Oxford Street, Cambridge, MA 02138, USA; William Sansum Diabetes Center, 2219 Bath Street, Santa Barbara, CA 93105.

Industrial & Engineering Chemistry Research
|December 13, 2016
PubMed
Summary

Three enhancements to artificial pancreas (AP) controllers improve autonomous blood glucose management for type 1 diabetes. These advancements personalize control, address glycemic extremes, and reduce hypoglycemia risk, enhancing safety and efficacy.

More Related Videos

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.5K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

8.3K

Related Experiment Videos

Last Updated: Mar 10, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.5K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

8.3K

Area of Science:

  • Biomedical Engineering
  • Control Systems Engineering
  • Endocrinology

Background:

  • Developing an effective artificial pancreas (AP) for autonomous insulin delivery in type 1 diabetes mellitus (T1DM) presents significant challenges.
  • Existing AP controllers require improvements to handle inter- and intra-individual variations in insulin sensitivity and glycemic fluctuations.

Purpose of the Study:

  • To propose and evaluate three enhancements to a model predictive controller (MPC) for autonomous blood glucose control in T1DM.
  • To improve the safety, personalization, and efficacy of AP systems through advanced control strategies.

Main Methods:

  • Expansion of the core MPC model with a personalization scheme to account for individual insulin sensitivity.
  • Incorporation of asymmetric weighting in the MPC cost function to address the differing impacts of hypoglycemia and hyperglycemia.
  • Development of an enhanced dynamic insulin-on-board algorithm to mitigate hypoglycemia after carbohydrate intake.
  • Evaluation through extensive *in silico* trials using a novel clinical protocol and simulated testing on clinical data.

Main Results:

  • The combined advancements demonstrated statistically significant improvements in glycemic control compared to the non-enhanced controller.
  • Increased time within the safe glycemic range (70-180 mg/dL) from 68.8% to 76.9%.
  • Increased time within the euglycemic range (80-140 mg/dL) from 44.5% to 48.1%, without a significant rise in hypoglycemia instances.

Conclusions:

  • The proposed enhancements offer a safe and effective approach to AP control, personalizing performance without complex model identification.
  • These advancements represent a significant step towards more robust and reliable automated insulin delivery systems for T1DM management.